Is Mounjaro good for PCOS — and could it be right for you?

What the trial data show, and where the gaps remain

Tirzepatide was studied primarily in adults with obesity or overweight plus at least one weight-related condition. The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults and found average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks. That level of weight loss is clinically meaningful for people with PCOS, because adipose tissue itself drives androgen production and worsens insulin resistance, both central features of the condition.

PCOS is characterised by a feedback loop: higher insulin levels stimulate the ovaries to produce more androgens, androgens impair ovulation, and weight gain tightens the loop further. Tirzepatide acts on both GIP and GLP-1 receptors, reducing appetite and slowing gastric emptying while also improving insulin sensitivity. Smaller studies and clinical case series have reported improvements in menstrual regularity and androgen markers alongside weight loss in women with PCOS using GLP-1-based treatments, though large, dedicated, randomised trials specifically in PCOS populations are still relatively sparse. The existing evidence is promising rather than definitive.

What is clear from the established data is that sustained weight loss of even 5–10% can restore ovulation in some women with PCOS. Tirzepatide consistently produces losses well above that threshold in suitable patients, which is why many endocrinologists and gynaecologists are watching the emerging PCOS literature closely. NICE's appraisal of tirzepatide (TA1026) does not address PCOS directly, but it does recommend the medicine for adults with a BMI of 35 or above plus at least one weight-related condition, and many women with PCOS will meet those criteria.

How PCOS fits the licensed eligibility criteria for Mounjaro in the UK

Tirzepatide is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition. PCOS is not explicitly named as a qualifying condition on the medicine's label, but several of its common features (type 2 diabetes, prediabetes, hypertension and dyslipidaemia) are. If you have PCOS and any of those comorbidities, a prescriber can legitimately consider tirzepatide within its licensed indication. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance.

The nuance matters. A woman with PCOS, a BMI of 31 and no other diagnosed conditions sits in a greyer area than someone with PCOS plus confirmed insulin resistance and raised triglycerides. That is precisely why a thorough clinical assessment comes before any prescribing decision. Our clinical team at nume reviews every consultation personally, a prescriber reads your answers and medical history, not an automated system.

It is also worth understanding that eligibility is not the same as suitability. Even where the BMI and comorbidity criteria are met, your prescriber will weigh other factors: your full medication list, any history of pancreatitis or certain GI conditions, thyroid history and your current reproductive plans. PCOS itself does not disqualify you, but the full picture always shapes the decision. You can explore the broader clinical overview of Mounjaro to understand what that assessment typically covers.

What to consider if you have PCOS and are planning a pregnancy

This is where the guidance is unambiguous. Mounjaro is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. The medicine should be stopped before conception; speak to your GP or a specialist to agree a plan, including how far in advance to stop and what monitoring makes sense during any transition.

The contraception picture adds an additional practical step. The MHRA advises that women using the oral contraceptive pill alongside tirzepatide should add a non-oral method (such as condoms) for the first four weeks of treatment and for four weeks after every dose increase, because slowed gastric emptying may reduce pill absorption. This applies specifically to tirzepatide; the equivalent concern has not been demonstrated to the same extent with semaglutide. NHS England's guidance on weight-management injections sets this out clearly and is worth reading alongside your prescriber's advice.

If you are using Mounjaro partly because you hope to improve fertility, be honest with your prescriber about that goal from the start. It shapes how they approach the medicine, when they might recommend stopping, and what reproductive health support to involve. More on the pregnancy considerations with Mounjaro is covered in a dedicated page if you want to read ahead of your consultation.

Side effects and interactions worth knowing about in a PCOS context

The side-effect profile of tirzepatide is broadly the same regardless of whether PCOS is in the picture. Gastrointestinal effects (nausea, loose stools, constipation and indigestion) are the most commonly reported, particularly in the first weeks after starting or after a dose increase. They tend to settle, though the timeline varies. Fatigue, headache and dizziness are also reported.

One interaction relevant to many women with PCOS involves metformin. It is widely prescribed for insulin resistance in PCOS, and some women take it alongside a GLP-1 or dual-agonist treatment. That combination is not automatically contraindicated, but the prescriber needs to know about it. Similarly, if you take any hormonal medications (including the pill for PCOS symptom management rather than purely for contraception) flagging these at consultation matters.

For a broader look at how tirzepatide relates to metabolic and hormonal conditions, the page on Mounjaro and type 2 diabetes covers the insulin-related evidence in more depth. If you are also curious about how the medicine may affect cardiovascular health, the page on whether Mounjaro is good for your heart explores what the trial data suggest. And for those managing fatty liver disease alongside PCOS, there is a dedicated page on whether Mounjaro is good for the liver that is worth reading before your consultation. If you have questions about how the medicine interacts with everyday choices, alcohol and Mounjaro is a practical starting point. These are prescription-only medicines, if any symptom concerns you during treatment, contact your prescriber or call 111 rather than waiting.

If you would like a prescriber to assess your full situation, you can check your eligibility with a free consultation today.